Treatment of esophageal carcinoma
Treatment of esophageal carcinoma
复制标题
DOI：
10.1378/chest.116.suppl_3.463s
复制
发表时间：
1999-12-01
期刊：
影响因子：
9.6
通讯作者：
Decker, G
中科院分区：
文献类型：
--
作者：
Lerut, T;Coosemans, W;Decker, G
食管和胃食管交界处的取消仍然是一个致命的恶性肿瘤，总体预后不良。特别是在西半球，腺癌的发病率急剧上升。在过去的二十年里，手术已成为治疗的主要手段。手术死亡率的降低和肿瘤学原则的标准化（重点是切除的完整性）被认为是提高5年生存率的原因，5年生存率达到或等于30%。到目前为止，除了在病理检查中显示完全缓解的患者子集外，使用化疗或放化疗的联合新辅助治疗方式还没有被证实的益处。进一步的研究应集中在新的化疗药物和分子标记物的发展，使更好地识别候选人的多模式方案。
Cancel of the esophagus and gastroesophageal junction remains a virulent malignancy with an overall poor prognosis. Especially in the Western hemisphere, the incidence of adenocarcinoma is sharply rising. Over the last two decades, surgery has become the mainstay of treatment. Decreased surgical mortality and standardization of oncologic principles focusing on the completeness of resection are believed to be responsible for the improved 5-year survival rates, which are reaching greater than or equal to 30%. Until now, there has been no proven benefit from combined neoadjuvant treatment modalities using chemotherapy or chemoradiotherapy except for the subset of patients showing a complete response at pathologic examination. Further research should focus on new chemotherapeutic agents and the development of molecular markers that allow better identification of candidates for multimodality regimens.